Genomics & Gene Editing
CRISPR editors + AI drug discovery — clinical-stage, binary readouts
Gene editing + computational/AI drug discovery — mostly clinical-stage, pre-revenue names whose value turns on binary trial readouts, anchored by one profitable, de-risked franchise. Curated structure; live delayed prices. Not investment advice.
CRISPR / Gene Editors
The editing platforms — one has an approved therapy, the rest are clinical-stage and binary on trial data. VRTX is the de-risked, profitable anchor (commercial CRISPR partner).
De-risked anchor: profitable mega-cap, commercial CRISPR partner (Casgevy) + dominant cystic-fibrosis franchise.
First approved CRISPR therapy (Casgevy, with VRTX) + pipeline; commercial-but-early.
In-vivo gene editing; positive Phase 3 (hereditary angioedema) — an in-vivo first.
Base-editing platform (more precise than cut-CRISPR); clinical-stage, pre-revenue.
Gene-editing; smallest and most troubled of the editors — very high risk, frequent strategy shifts.
AI Drug Discovery & Precision Medicine
Computational / AI platforms designing molecules + reading genomic-clinical data. Mostly pre-profit, partnership-milestone-driven.
Physics-based computational drug-design software + an internal pipeline — dual software + biotech value.
Image-based AI drug-discovery platform (absorbed Exscientia in 2024); pre-profit.
AI precision-medicine / diagnostics platform (genomic + clinical data); high-growth.
Generative-AI antibody design; small-cap, pre-commercial, partnership-milestone-driven.
Motion-based / computational drug discovery; clinical-stage, binary on trial readouts.
Curated structure · live delayed prices from public data · for reference only · not investment advice